Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anju Ghangurde

Executive Editor, APAC

Mumbai, India

Anju has been a journalist since 1993 including stints at India's leading financial dailies. She covers a range of topics across the pharma and biosimilar landscape. Drug pricing, policy and regulatory affairs, M&A and patents are areas of special interest to her. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.

Latest From Anju Ghangurde

US NCI’s Gravitt On Stepping Up Cancer Control Efforts In Asia-Pacific

Dr Patti Gravitt, Deputy Director, Center for Global Health, US National Cancer Institute, in an interview with Scrip, discusses a range of strategies underway and proposed to strengthen cancer control efforts in the Asia Pacific. HPV vaccination and a regional cancer control dashboard are among the areas she highlighted.

Policy Cancer

ChatGPT Unleashed: Generative AI Use Cases Taking Off In Pharma

As generative AI and its star avatar, ChatGPT, take the world by storm, pharma is seeing traction for use cases around smarter pharmacovigilance and commercial marketing content development, among others. Senior executives from Indegene discuss this and more in an interview with Scrip.

Commercial Artificial Intelligence

Dr Reddy’s CEO: We’re In ‘Great Dialogue’ With The Innovation Industry In China

Dr Reddy’s is collaborating with innovator firms in China, Israel and the US largely in areas of unmet need, propelling its “Horizon-2” strategy that encompasses segments like biologics and cell and gene therapy, digital services and immuno-oncology NCEs, among others.

Strategy Deals

First Cetuximab Biosimilar Debuts In India; Merck KGaA Sticks To Guns

Alkem’s ‘affordable’ cetuximab biosimilar set to take on Erbitux in India, even as Merck KGaA pursues a court case seeking information and data related to efficacy and interchangeability of the Indian company's product.

Biosimilars Commercial

Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’

Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.

Sales & Earnings Commercial

Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’

Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.

Commercial Biosimilars
See All
UsernamePublicRestriction

Register